Type 2 diabetes combined with overweight/obesity
Conditions
Interventions
Experimental group:Semaglutide
Control group:Metformin
Sponsors
the First Affiliated Hospital of Shihezi University Medical School
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meeting the 1999 World Health Organization (WHO) diagnostic criteria for patients with type 2 diabetes: typical diabetes symptoms (polydipsia, polyuria, polydipsia, weight loss) plus random blood glucose >=11.1mmol/L, or fasting blood glucose >=7.0mmol/L or blood glucose >=11.1mmol/L within 2 hours after glucose loading. Those who do not have diabetes symptoms need to repeat the examination on another day to confirm the diagnosis; 2. Aged 18-75 years old; 3. Body mass index (BMI) >= 25kg/m2; 4. Glycosylated hemoglobin: 6.5% ~ 9.0%; 5. Agree and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergic to any excipients in Semaglutide or dagliagin; 2. Personal and family history of medullary thyroid cancer and multiple endocrine adenomatosis type 2; 3. Secondary obesity caused by drug use and other endocrine diseases; 4. Type l diabetes, gestational diabetes and other special types of diabetes; 5. Acute complications of severe diabetes such as diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome, hypoglycemia and other diseases that may affect glucose metabolism; 6. Pregnant, pregnant or lactating women, long-term bedridden; 7. Previous bariatric surgery, use of other types of GLP-1RA or weight-loss drugs in the 3 months before enrollment; 8. Severe stress, acute infection, severe cardiac insufficiency, severe liver and kidney dysfunction, acute and chronic pancreatitis, stroke within 6 months, history of surgery or trauma within 6 months; 9. Patients with severe renal impairment (eGFR<30mL/min/1.73m2, end-stage renal disease or requiring dialysis); 10. Patients who voluntarily discharged from the hospital or refused to follow the interviewer without medical reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight of subjects before and after treatment in both groups; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body mass index, BMI;Waistline;Hipline;Biceps circumference;Fasting blood glucose;HbA1c;Blood pressure;Blood lipid;Liver function;Renal function; | — |
Countries
China
Contacts
Public ContactHuo Rui; Sha Huimin
the First Affiliated Hospital of Shihezi University Medical School
Outcome results
None listed